FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Evidence |
| Id | Evidence-236975.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Evidence 236975
version: 70; Last updated: 2025-10-07 17:12:54+0000; Language: en
Profile: ComparativeEvidence
url: https://fevir.net/resources/Evidence/236975
identifier: FEvIR Object Identifier/236975, outcomeId/313963, picoId/85798, sectionId/73215
name: Serious_hyperglycaemia_from_MAGICapp_313963
title: MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
citeAs:
MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236975. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236975. Computable resource at: https://fevir.net/resources/Evidence/236975#json.
status: Active
author: Computable Publishing®: MAGIC-to-FEvIR Converter:
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
| Code | Value[x] |
| Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) | ComparativeEvidence |
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
| Type | Target[x] |
| Part Of | MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report) |
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
assertion:
There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of serious hyperglycaemia.
variableDefinition
description:
Adults with type 2 diabetes
variableRole: Population
variableDefinition
description:
GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
variableRole: Exposure
comparatorCategory: GLP-1 RA
variableDefinition
description:
Serious hyperglycaemia
variableRole: Outcome
observed: Serious hyperglycaemia
synthesisType: SYSTEMATIC_REVIEW
studyDesign: randomized assignment
statistic
description:
Risk Difference 0.5% (CI95 -0.2% to 1.9%)
statisticType: risk difference
quantity: 0.005
SampleSizes
NumberOfStudies NumberOfParticipants 1 463 AttributeEstimates
Type Range CI95 -0.002-0.019
statistic
description:
OR 1.48 (CI95 0.75 to 2.93)
statisticType: odds ratio
quantity: 1.48
SampleSizes
NumberOfStudies NumberOfParticipants 1 463 AttributeEstimates
Type Range CI95 0.75-2.93
certainty
type: Overall certainty
rating: High certainty
Subcomponents
Type Rating Risk of Bias NOTSET Inconsistency NOTSET Indirectness NOTSET Imprecision NONE Publication Bias NOTSET
{
"resourceType": "Evidence",
"id": "236975",
"meta": {
"versionId": "70",
"lastUpdated": "2025-10-07T17:12:54.639Z",
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
"language": "en",
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"url": "https://fevir.net/resources/Evidence/236975",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "236975",
"assigner": {
"display": "Computable Publishing LLC"
}
},
{
"type": {
"text": "outcomeId"
},
"system": "https://app.magicapp.org/#/guidelines",
"value": "313963"
},
{
"type": {
"text": "picoId"
},
"system": "https://app.magicapp.org/#/guidelines",
"value": "85798"
},
{
"type": {
"text": "sectionId"
},
"system": "https://app.magicapp.org/#/guidelines",
"value": "73215"
}
],
"name": "Serious_hyperglycaemia_from_MAGICapp_313963",
"title": "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"citeAs": "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236975. Revised 2025-10-07. Available at: https://fevir.net/resources/Evidence/236975. Computable resource at: https://fevir.net/resources/Evidence/236975#json.",
"status": "active",
"author": [
{
"name": "Computable Publishing®: MAGIC-to-FEvIR Converter"
}
],
"publisher": "Computable Publishing LLC",
"contact": [
{
"telecom": [
{
"system": "email",
"value": "support@computablepublishing.com"
}
]
}
],
"useContext": [
{
"code": {
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "evidence-communication",
"display": "Evidence Communication"
},
"valueCodeableConcept": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/179423",
"code": "ComparativeEvidence",
"display": "ComparativeEvidence"
}
]
}
}
],
"copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"relatesTo": [
{
"type": "part-of",
"targetReference": {
"type": "Composition",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-conversion-report",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
}
}
],
"description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"assertion": "There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of serious hyperglycaemia.",
"variableDefinition": [
{
"description": "Adults with type 2 diabetes",
"variableRole": "population",
"observed": {
"reference": "Group/236947",
"type": "Group",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-population-group-85394-85798",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Adults with type 2 diabetes and CVD and CKD"
}
},
{
"description": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA",
"variableRole": "exposure",
"comparatorCategory": "GLP-1 RA",
"observed": {
"reference": "EvidenceVariable/236950",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-group-assignment-85394-85798",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA"
}
},
{
"description": "Serious hyperglycaemia",
"variableRole": "outcome",
"observed": {
"reference": "EvidenceVariable/236974",
"type": "EvidenceVariable",
"identifier": {
"type": {
"text": "FEvIR Linking Identifier"
},
"system": "https://fevir.net/FLI",
"value": "MAGIC-5288-j1Wqrn-313963",
"assigner": {
"display": "Computable Publishing LLC"
}
},
"display": "Serious hyperglycaemia"
}
}
],
"synthesisType": [
{
"text": "SYSTEMATIC_REVIEW"
}
],
"studyDesign": [
{
"coding": [
{
"system": "http://hl7.org/fhir/study-design",
"code": "SEVCO:01003",
"display": "randomized assignment"
}
]
}
],
"statistic": [
{
"description": "Risk Difference 0.5% (CI95 -0.2% to 1.9%)",
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000424",
"display": "risk difference"
}
]
},
"quantity": {
"value": 0.005
},
"sampleSize": {
"numberOfStudies": 1,
"numberOfParticipants": 463
},
"attributeEstimate": [
{
"type": {
"text": "CI95"
},
"range": {
"low": {
"value": -0.002
},
"high": {
"value": 0.019
}
}
}
]
},
{
"description": "OR 1.48 (CI95 0.75 to 2.93)",
"statisticType": {
"coding": [
{
"system": "https://fevir.net/sevco",
"code": "STATO:0000182",
"display": "odds ratio"
}
]
},
"quantity": {
"value": 1.48
},
"sampleSize": {
"numberOfStudies": 1,
"numberOfParticipants": 463
},
"attributeEstimate": [
{
"type": {
"text": "CI95"
},
"range": {
"low": {
"value": 0.75
},
"high": {
"value": 2.93
}
}
}
]
}
],
"certainty": [
{
"type": {
"coding": [
{
"system": "http://hl7.org/fhir/certainty-type",
"code": "Overall",
"display": "Overall certainty"
}
]
},
"rating": {
"coding": [
{
"system": "https://fevir.net/resources/CodeSystem/27834",
"code": "RJCS-2003",
"display": "High certainty"
}
]
},
"subcomponent": [
{
"type": {
"text": "Risk of Bias"
},
"rating": {
"text": "NOTSET"
}
},
{
"type": {
"text": "Inconsistency"
},
"rating": {
"text": "NOTSET"
}
},
{
"type": {
"text": "Indirectness"
},
"rating": {
"text": "NOTSET"
}
},
{
"type": {
"text": "Imprecision"
},
"rating": {
"text": "NONE"
}
},
{
"type": {
"text": "Publication Bias"
},
"rating": {
"text": "NOTSET"
}
}
]
}
]
}